Age-related macular degeneration and nutritional supplementation: a review of randomised controlled trials

Hannah E. Bartlett*, Frank Eperjesi

*Corresponding author for this work

Research output: Contribution to journalArticle


Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world. The lack of effective treatment modalities, coupled with evidence supporting an oxidative pathogenesis, has increased interest in the potential preventative role of nutritional supplementation. This article reviews seven randomised controlled trials (RCTs) that have investigated the role of nutritional supplementation in AMD. Three of these trials reported a positive effect of nutritional supplementation on AMD; the Age-related eye study (AREDS), the Lutein Antioxidant Supplementation Trial (LAST), and the oral zinc trial by Newsome et al. (1988). However, the oral zinc trial by Newsome et al. (1988) was unlikely to detect any difference between treatments smaller than 72%, and the AREDS results were based on a subgroup of their study population. Lutein was considered for the AREDS formulation, but was not commercially available at that time. The findings of the LAST support a possible therapeutic role of lutein in AMD. © 2004 The College of Optometrists.

Original languageEnglish
Pages (from-to)383-399
Number of pages17
JournalOphthalmic and Physiological Optics
Issue number5
Publication statusPublished - 2 Sep 2003


Bibliographical note

© 2003 The College of Optometrists. Published by Wiley-Blackwell.


  • age-related macular degeneration
  • antioxidants
  • carotenoids
  • lutein
  • randomised controlled trials

Cite this